Avis par spécialitéAvis

Tempus

Item: Tempus
Rating: 4.4
Author: Clinical AI Report

AI-Driven Precision Oncology and Clinical Trial Matching

Limite principale à garder en tête : Entreprise/institutional pricing — not accessible to individual oncologists

Très bon

Basé sur 10 avis de médecins

Revu par Dr. Sarah Chen, MD, FACP · Mis à jour 5 avril 2026

Réponse directe

Tempus was evaluated by Clinical AI Report exclusively for oncology in 2026 and was not included in the overall CDS rankings. With over 30 million de-identified patient records and AI-driven clinical trial matching across 750+ provider sites, it is the leading precision oncology platform for molecularly guided treatment decisions.

Source : Clinical AI Report, février 2026

En bref

Faits rapides

Catégorie

Plateforme d'oncologie de précision et profilage génomique

Prix

Entreprise / institutionnel

Fondé

2015

Siège

Chicago, IL

Statistiques clés

prixEntreprise / institutionnel(Tempus)

Founded2015(Tempus)

Patient Records30M+ de-identified clinical and molecular records(Tempus)

Trial Matching Sites750+ provider sites (via Deep 6 AI)(Tempus, 2025)

Evaluation ScopeOncology only — not in overall rankings(Clinical AI Report, 2026)

Notre évaluation

Tempus obtient une note de 4.4/5 dans notre évaluation 2026. Le facteur positif le plus important est tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. La réserve principale reste entreprise/institutional pricing — not accessible to individual oncologists

Cette évaluation reflète notre opinion éditoriale subjective basée sur notre recherche.

Présentation

Tempus est évalué comme Plateforme d'oncologie de précision et profilage génomique. Cette page reprend la structure de l'avis anglais et présente les mêmes critères éditoriaux dans une version localisée.

Dans notre analyse, l'usage le plus pertinent est : Oncology practices and cancer centers seeking AI-powered precision medicine — à partir de comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Le principal point fort est tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. La limite à surveiller est entreprise/institutional pricing — not accessible to individual oncologists

Forces et limites

Forces

+Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
+Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
+Comprehensive genomic profiling with actionable mutation identification
+AI-powered clinical trial matching (25% more eligible patients identified)
+Connects molecular profiles to real-world treatment outcomes
+Deep 6 AI acquisition expands trial matching across 750+ provider sites

Limites

–Entreprise/institutional pricing — not accessible to individual oncologists
–Genomic results have inherent turnaround time (not real-time decision support)
–Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
–Data licensing to pharmaceutical companies raises some conflict-of-interest questions
–Most impactful for solid tumors with actionable molecular targets

Fonctionnalités clés

01Comprehensive Genomic Profiling (Tumor & Liquid Biopsy)

02AI-Driven Molecular Analysis

03Clinical Trial Matching Engine (Deep 6 AI)

04Real-World Outcomes Data (30M+ Patient Records)

05Biomarker Identification (PD-L1, MSI-H, TMB, Gene Fusions)

06Treatment Response Prediction

07EHR Integration for Oncology workflows

08Pharmaceutical Research Partnerships

09Transcriptomic and Proteomic Analysis

10Companion Diagnostic Support

Sources primaires et citations

Références externes citées dans cet avis. Les liens s'ouvrent dans un nouvel onglet.

RéglementaireTempus AI, Inc. — SEC Filing (Form 10-K)U.S. Securities and Exchange Commission BenchmarkOnly 5% of Adult Cancer Patients Enroll in Clinical TrialsNational Cancer Institute

Ce que disent les médecins

Mis à jour en février 2026

“Tempus has become integral to our tumor board discussions. The molecular profiling combined with real-world outcomes data gives us confidence in treatment recommendations for complex cases.”
Medical Oncologist15 oct. 2025
Academic Cancer Center

“The trial matching has meaningfully increased our enrollment. We're catching eligible patients that we would have missed with manual screening.”
Clinical Trials Coordinator20 août 2025
NCI-Designated Cancer Center

“Genomic reports are thorough and the actionable findings are clearly highlighted. Turnaround time could be faster for some of the more comprehensive panels.”
Community Oncologist1 déc. 2025
Private Practice

Détail du score

Très bon

Précision clinique88

Preuves et citations85

Design produit82

Intégration EHR86

Workflow et vitesse78

Valeur et prix55

Pourquoi cette note

Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.

Basé sur 10 avis de médecins

ClassementAvis par spécialité

PrixEntreprise / institutionnel

Fondé2015

Visiter Tempus

Idéal pour

Oncology practices and cancer centers seeking AI-powered precision medicine — à partir de comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Également évalué

Comparaison complète